GO:2001186 negative regulation of CD8-positive, alpha-beta T cell activation: Immune Checkpoint Control, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:2001186 describes any biological process that stops, prevents, or reduces the frequency, rate, or extent of CD8-positive, alpha-beta T cell activation.
• Negative regulation of CD8 T cell activation is essential for preventing autoimmunity and limiting immunopathology during infection.
• Key negative regulators include signaling lymphocyte activation molecule-associated protein (SAP), Notch/RBP-J signaling, and double-negative regulatory T cells.
• Type I interferon-induced, NKT cell-mediated signals can negatively control CD8 T cell priming by dendritic cells.
• Thymic selection and post-thymic regulation shape the CD8 T cell repertoire and its responsiveness to activation signals.
• CRISPR knockout, point mutation, knock-in, and overexpression models enable causal dissection of negative regulatory pathways in CD8 T cell activation.
Description
CD8-positive, alpha-beta T cells are critical effectors of adaptive immunity, but their activation must be tightly controlled to avoid autoimmunity and excessive tissue damage. The Gene Ontology term GO:2001186, negative regulation of CD8-positive, alpha-beta T cell activation, captures the processes that stop, prevent, or reduce the frequency, rate, or extent of CD8-positive, alpha-beta T cell activation. This term is of high interest to immunologists because dysregulated CD8 T cell activation underlies autoimmune diabetes, graft rejection, and chronic inflammatory diseases, while insufficient negative regulation can contribute to immunopathology. Understanding the molecular players that enforce this checkpoint is therefore central to both basic immunology and therapeutic development. Research into GO:2001186 has revealed multiple layers of control, including cell-intrinsic inhibitory receptors, soluble mediators, and regulatory cell populations. For example, signaling lymphocyte activation molecule-associated protein (SAP) acts as a negative regulator of the CD8 T cell response in mice, and type I interferon-induced, NKT cell-mediated signals can negatively control CD8 T cell priming by dendritic cells. In addition, double-negative regulatory T cells can suppress immune responses through contact-dependent and cytokine-mediated mechanisms. These findings highlight the diversity of negative regulatory circuits that converge on CD8 T cell activation. This article provides a research-grade overview of GO:2001186, integrating the QuickGO definition with verified PubMed literature. We cover the biological process, key genes, disease relevance, and experimental models, including CRISPR-based approaches for functional validation. The goal is to support researchers in designing robust studies of negative regulation in CD8 T cell biology.
negative regulation of CD8-positive, alpha-beta T cell activation At A Glance
| GO ID | GO:2001186 |
|---|---|
| GO term | negative regulation of CD8-positive, alpha-beta T cell activation |
| Ontology | biological_process |
| Synonym | none |
| Major function | Stops, prevents, or reduces the frequency, rate, or extent of CD8-positive, alpha-beta T cell activation |
| Related cell type | CD8-positive, alpha-beta T cells |
| Key regulatory examples | SAP, Notch/RBP-J signaling, double-negative regulatory T cells, type I IFN/NKT cell axis |
| Disease relevance | Autoimmune diabetes, graft rejection, chronic inflammation |
What Is GO:2001186?
GO:2001186, negative regulation of CD8-positive, alpha-beta T cell activation, is a biological process that encompasses any mechanism that stops, prevents, or reduces the frequency, rate, or extent of CD8-positive, alpha-beta T cell activation. This includes cell-intrinsic checkpoints, soluble inhibitory factors, and regulatory cell populations that dampen CD8 T cell priming, expansion, or effector function. The term is distinct from positive regulation and from general T cell inhibition, as it specifically applies to CD8-positive, alpha-beta T cells.
Why Is negative regulation of CD8-positive, alpha-beta T cell activation Important in Cell Biology?
Negative regulation of CD8-positive, alpha-beta T cell activation is essential for immune homeostasis and for preventing autoimmunity and immunopathology. Without adequate negative regulation, CD8 T cells can attack self-tissues, as seen in autoimmune diabetes models. Conversely, excessive negative regulation can impair pathogen clearance and antitumor immunity. Understanding GO:2001186 therefore has direct implications for vaccine design, cancer immunotherapy, and treatment of autoimmune diseases.
• Prevents autoimmunity by limiting self-reactive CD8 T cell activation.
• Controls immunopathology during chronic infections.
• Shapes the peripheral CD8 T cell repertoire and differentiation state.
• Influences antitumor immunity and response to immunotherapy.
• Involved in graft rejection and transplant tolerance.
• Provides targets for therapeutic modulation of CD8 T cell responses.
• Regulates thymic selection and post-thymic CD8 T cell development.
• Double-negative regulatory T cells contribute to suppression of CD8 T cell responses.
• Notch/RBP-J signaling regulates peripheral T cell responses.
• Type I IFN-induced NKT cell-mediated negative control of CD8 T cell priming.
What Happens During negative regulation of CD8-positive, alpha-beta T cell activation?
Cell-intrinsic inhibitory checkpoints
In simple terms: Inside the T cell, certain molecules act like brakes to stop activation.
Signaling lymphocyte activation molecule-associated protein (SAP) functions as a negative regulator of the CD8 T cell response in mice. SAP deficiency or modulation can alter the threshold for CD8 T cell activation, demonstrating that cell-intrinsic factors can directly dampen activation signals. This checkpoint operates downstream of T cell receptor engagement and modulates the magnitude of the response.
Regulatory cell populations
In simple terms: Some specialized immune cells tell CD8 T cells to calm down.
Double-negative regulatory T cells (CD4- CD8- TCR alpha beta+) can suppress immune responses, including CD8 T cell activation, through contact-dependent and cytokine-mediated mechanisms. These cells have been isolated from human peripheral blood and can inhibit antigen-specific T cell responses. Their suppressive function represents a key layer of negative regulation in GO:2001186.
Cytokine and innate immune-mediated control
In simple terms: Signals from innate immune cells can put the brakes on CD8 T cell priming.
Type I interferon-induced, NKT cell-mediated signals can negatively control CD8 T cell priming by dendritic cells. This pathway involves cross-talk between innate-like NKT cells and dendritic cells, leading to reduced CD8 T cell activation. Such mechanisms are important for preventing excessive CD8 T cell responses during early immune activation.
Notch/RBP-J signaling in peripheral T cell responses
In simple terms: The Notch pathway can influence how T cells respond after they leave the thymus.
Notch/RBP-J signaling regulates alpha beta/gamma delta T cell lineage commitment and peripheral T cell responses. Disruption of this pathway alters the balance of T cell activation and can affect CD8 T cell responsiveness. This indicates that Notch/RBP-J signaling contributes to the negative regulation of CD8-positive, alpha-beta T cell activation in the periphery.
Thymic and post-thymic regulation
In simple terms: The thymus and events after it shape how easily CD8 T cells can be activated later.
Thymic differentiation of TCR alpha beta+ CD8 alpha alpha+ intraepithelial lymphocytes and post-thymic regulation of diabetogenic CD8 T cell development demonstrate that negative regulation begins during development. In TCR transgenic nonobese diabetic (NOD) mice, thymic and post-thymic mechanisms control the emergence of pathogenic CD8 T cells. Preselection TCR repertoire features can predict CD4 and CD8 T cell differentiation state, linking repertoire selection to later activation potential.
Key Genes Involved in GO:2001186 negative regulation of CD8-positive, alpha-beta T cell activation
The following genes and proteins have been implicated in the negative regulation of CD8-positive, alpha-beta T cell activation, based on verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SH2D1A (SAP) | Negative regulator of CD8 T cell response in mice | Knockout and point mutation models to study CD8 T cell hyperactivation |
| RBPJ | Mediates Notch/RBP-J signaling in T cell lineage commitment and peripheral responses | Conditional knockout to dissect peripheral CD8 T cell regulation |
| Notch receptors (e.g., NOTCH1) | Upstream of RBP-J in T cell lineage and peripheral responses | Overexpression and knockout to modulate CD8 T cell activation |
| TCR alpha beta | Antigen recognition and activation of CD8 T cells | Transgenic TCR models to track antigen-specific CD8 T cells |
| CD8 alpha alpha | Marker of intraepithelial lymphocytes and subset differentiation | Lineage tracing and knockout to study CD8 T cell subsets |
| IFNAR1 | Type I IFN receptor mediating NKT cell-dependent negative control | Knockout to test type I IFN effects on CD8 T cell priming |
| NKT cell TCR (e.g., Vα14-Jα18) | NKT cell-mediated negative control of CD8 T cell priming | Transgenic and knockout models to study NKT-CD8 cross-talk |
| FOXP3 | Regulatory T cell lineage factor; may influence double-negative regulatory T cells | Knockout and reporter models to assess regulatory T cell suppression |
| CD4 | Marker used to define double-negative regulatory T cells | Knockout and sorting to isolate DN Tregs |
| CD8 | Coreceptor defining CD8-positive, alpha-beta T cells | Knockout and knock-in to track CD8 T cell activation |
| IL-10 | Immunosuppressive cytokine potentially involved in DN Treg suppression | Overexpression and knockout to test suppression of CD8 T cells |
| TGF-beta | Immunosuppressive cytokine potentially involved in DN Treg suppression | Overexpression and knockout to test suppression of CD8 T cells |
| PD-1 (PDCD1) | Inhibitory receptor that can dampen CD8 T cell activation | Knockout and overexpression to study checkpoint function |
| CTLA-4 | Inhibitory receptor that can dampen T cell activation | Knockout and overexpression to study checkpoint function |
| LAG-3 | Inhibitory receptor that can dampen T cell activation | Knockout and overexpression to study checkpoint function |
| TIM-3 (HAVCR2) | Inhibitory receptor that can dampen T cell activation | Knockout and overexpression to study checkpoint function |
| TIGIT | Inhibitory receptor that can dampen T cell activation | Knockout and overexpression to study checkpoint function |
| CD28 | Costimulatory receptor whose blockade can reduce CD8 T cell activation | Knockout and point mutation to study costimulation |
How Is negative regulation of CD8-positive, alpha-beta T cell activation Regulated?
The negative regulation of CD8-positive, alpha-beta T cell activation is itself controlled by multiple signaling pathways. Type I interferon signaling can induce NKT cell-mediated negative control of CD8 T cell priming by dendritic cells. Notch/RBP-J signaling regulates peripheral T cell responses and lineage commitment, thereby influencing the threshold for CD8 T cell activation. Additionally, double-negative regulatory T cells can suppress CD8 T cell responses through contact-dependent and cytokine-mediated mechanisms, including potential roles for IL-10 and TGF-beta. Thymic selection and post-thymic events also set the stage for later responsiveness, as shown in TCR transgenic NOD mice. These regulatory layers ensure that CD8 T cell activation is appropriately dampened when necessary.
negative regulation of CD8-positive, alpha-beta T cell activation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SH2D1A (SAP) | CD8 T cell hyperactivation and autoimmunity | Knockout mouse and point mutation knock-in |
| RBPJ | T cell lineage commitment and peripheral responses | Conditional knockout in T cells |
| IFNAR1 | Type I IFN-mediated negative control of CD8 T cell priming | Knockout mouse and NKT cell co-culture |
| FOXP3 | Regulatory T cell suppression and autoimmunity | Knockout and reporter mice |
| PDCD1 (PD-1) | Cancer immunotherapy and autoimmunity | Knockout and overexpression models |
Autoimmune diabetes
In TCR transgenic nonobese diabetic (NOD) mice, thymic and post-thymic regulation of diabetogenic CD8 T cell development is critical for preventing autoimmune diabetes. Defects in negative regulation of CD8-positive, alpha-beta T cell activation can lead to escape of autoreactive CD8 T cells and beta cell destruction. This model highlights GO:2001186 as a key checkpoint in autoimmune disease.
Graft rejection and transplant tolerance
Double-negative regulatory T cells can suppress immune responses, including CD8 T cell activation, and may influence graft rejection. Their ability to inhibit antigen-specific T cell responses suggests that enhancing negative regulation could promote transplant tolerance. Thus, GO:2001186 is relevant to transplantation immunology.
Chronic inflammation and immunopathology
Type I IFN-induced, NKT cell-mediated negative control of CD8 T cell priming by dendritic cells helps limit excessive inflammation. When this negative regulation fails, CD8 T cell hyperactivation can contribute to chronic inflammatory diseases. Understanding these pathways may reveal therapeutic targets to dampen immunopathology.
Cancer immunotherapy
Inhibitory receptors such as PD-1, CTLA-4, LAG-3, TIM-3, and TIGIT can negatively regulate CD8 T cell activation. Blocking these checkpoints enhances antitumor immunity, but also risks autoimmunity. Therefore, GO:2001186 is central to the balance between tumor control and immune-related adverse events.
From negative regulation of CD8-positive, alpha-beta T cell activation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does SAP negatively regulate CD8 T cell activation? | SH2D1A knockout and point mutation knock-in mice |
| How does Notch/RBP-J signaling affect peripheral CD8 T cell responses? | RBPJ conditional knockout and Notch overexpression |
| Do double-negative regulatory T cells suppress CD8 T cell activation? | Adoptive transfer of DN Tregs and co-culture suppression assays |
| Does type I IFN-induced NKT cell signaling negatively control CD8 T cell priming? | IFNAR1 knockout and NKT cell-deficient mice |
| How does thymic selection influence diabetogenic CD8 T cells? | TCR transgenic NOD mice |
| Can checkpoint receptors be modulated to enhance antitumor immunity? | PD-1, CTLA-4, LAG-3, TIM-3, TIGIT knockout and overexpression models |
How to Study the negative regulation of CD8-positive, alpha-beta T cell activation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Flow cytometry | Frequency and phenotype of activated CD8 T cells | Tracking antigen-specific CD8 T cell responses |
| TCR repertoire sequencing | Diversity and differentiation state prediction | Linking preselection repertoire to CD8 T cell fate |
| Suppression assay | Inhibition of CD8 T cell activation by regulatory cells | Testing DN Treg function |
| CRISPR knockout | Loss-of-function effects on CD8 T cell activation | Validating negative regulators |
| CRISPR knock-in | Tagging or point mutations in candidate genes | Tracking protein localization and function |
| Overexpression | Gain-of-function effects on CD8 T cell activation | Testing sufficiency of negative regulators |
| Cytokine profiling | Levels of IL-10, TGF-beta, and other suppressive cytokines | Assessing mechanisms of DN Treg suppression |
| Adoptive transfer | In vivo suppression of CD8 T cell responses | Testing regulatory cell function in disease models |
Flow cytometry and tetramer staining
Flow cytometry with peptide-MHC tetramers allows enumeration and phenotyping of antigen-specific CD8 T cells, enabling assessment of activation status and negative regulation. This method is widely used to track CD8 T cell responses in models of autoimmunity and infection.
TCR repertoire sequencing
Preselection TCR repertoire analysis can predict CD4 and CD8 T cell differentiation state, providing insights into how repertoire features influence later activation potential. This approach helps link thymic selection to peripheral negative regulation.
Suppression assays with regulatory T cells
In vitro suppression assays using double-negative regulatory T cells and responder CD8 T cells can quantify negative regulation of activation. These assays are useful for testing contact-dependent and cytokine-mediated mechanisms.
Genetic knockout and knock-in models
CRISPR-based knockout, point mutation, and knock-in models enable causal testing of candidate genes in negative regulation of CD8 T cell activation. For example, SH2D1A knockout and RBPJ conditional knockout mice have been used to dissect these pathways.
How CRISPR Can Be Used to Study GO:2001186 negative regulation of CD8-positive, alpha-beta T cell activation
Knockout
CRISPR knockout of candidate genes such as SH2D1A or RBPJ can reveal their role in negative regulation of CD8-positive, alpha-beta T cell activation. Loss-of-function models show whether a gene is required to dampen CD8 T cell responses.
Point Mutation
Point mutation knock-in can model disease-associated variants or disrupt specific domains, allowing fine mapping of negative regulatory functions. This approach is useful for dissecting signaling domains in SAP or Notch pathway components.
Knock-in
Tagged knock-in of endogenous genes enables tracking of protein expression and localization in CD8 T cells without overexpression artifacts. This helps validate where and when negative regulators act during activation.
Overexpression
Overexpression of candidate negative regulators can test sufficiency for suppressing CD8 T cell activation. This is particularly useful for checkpoint receptors like PD-1 or CTLA-4.
How EDITGENE Supports negative regulation of CD8-positive, alpha-beta T cell activation Research
Researchers studying negative regulation of CD8-positive, alpha-beta T cell activation-related genes often need to determine whether a candidate gene is causally involved in dampening CD8 T cell responses. EDITGENE provides CRISPR-based cell models and screening services to accelerate this functional validation, from knockout to knock-in and overexpression.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of CD8-positive, alpha-beta T cell activation research.
Frequently Asked Questions About negative regulation of CD8-positive, alpha-beta T cell activation
What is GO:2001186?
GO:2001186 is the Gene Ontology term for negative regulation of CD8-positive, alpha-beta T cell activation, describing any process that stops, prevents, or reduces the frequency, rate, or extent of CD8-positive, alpha-beta T cell activation.
What genes are involved in negative regulation of CD8-positive, alpha-beta T cell activation?
Key genes include SH2D1A (SAP), RBPJ, Notch receptors, IFNAR1, FOXP3, and checkpoint receptors such as PDCD1 (PD-1), CTLA-4, LAG-3, TIM-3, and TIGIT.
How does SAP negatively regulate CD8 T cell responses?
SAP, encoded by SH2D1A, acts as a negative regulator of the CD8 T cell response in mice, modulating activation thresholds downstream of TCR signaling.
What role do double-negative regulatory T cells play in CD8 T cell suppression?
Double-negative regulatory T cells (CD4- CD8- TCR alpha beta+) can suppress immune responses, including CD8 T cell activation, through contact-dependent and cytokine-mediated mechanisms.
How does type I interferon signaling negatively control CD8 T cell priming?
Type I interferon-induced, NKT cell-mediated signals can negatively control CD8 T cell priming by dendritic cells, limiting excessive CD8 T cell activation.
What is the role of Notch/RBP-J signaling in CD8 T cell activation?
Notch/RBP-J signaling regulates alpha beta/gamma delta T cell lineage commitment and peripheral T cell responses, influencing the negative regulation of CD8 T cell activation.
Which diseases are linked to defective negative regulation of CD8 T cell activation?
Defective negative regulation is linked to autoimmune diabetes, graft rejection, chronic inflammation, and cancer immunotherapy outcomes.
How can CRISPR be used to study negative regulation of CD8 T cell activation?
CRISPR knockout, point mutation, knock-in, and overexpression models allow causal testing of candidate genes in negative regulation of CD8 T cell activation.
What experimental models are used to study GO:2001186?
Models include SH2D1A knockout mice, RBPJ conditional knockout mice, IFNAR1 knockout mice, TCR transgenic NOD mice, and adoptive transfer of double-negative regulatory T cells.
What methods measure negative regulation of CD8 T cell activation?
Flow cytometry, TCR repertoire sequencing, suppression assays, cytokine profiling, and CRISPR-based genetic models are commonly used.
Conclusion
GO:2001186, negative regulation of CD8-positive, alpha-beta T cell activation, is a critical biological process that safeguards against autoimmunity and immunopathology while shaping effective immune responses. Key regulators include SAP, Notch/RBP-J signaling, double-negative regulatory T cells, and type I IFN-induced NKT cell-mediated control. Understanding these pathways has direct implications for autoimmune disease, transplantation, and cancer immunotherapy. CRISPR-based models from EDITGENE can accelerate functional validation of candidate genes in this pathway, enabling researchers to move from correlation to causation.
References
- 1. Lambolez F et al.. 2007. Thymic differentiation of TCR alpha beta(+) CD8 alpha alpha(+) IELs.. Immunol Rev 215:178-88 PMID: 17291288
- 2. Fischer K et al.. 2005. Isolation and characterization of human antigen-specific TCR alpha beta+ CD4(-)CD8- double-negative regulatory T cells.. Blood 105(7):2828-35 PMID: 15572590
- 3. Hou X et al.. 2020. Preselection TCR repertoire predicts CD4(+) and CD8(+) T-cell differentiation state.. Immunology 161(4):354-363 PMID: 32875554
- 4. Chen G et al.. 2005. Signaling lymphocyte activation molecule-associated protein is a negative regulator of the CD8 T cell response in mice.. J Immunol 175(4):2212-8 PMID: 16081788
- 5. Bochtler P et al.. 2008. Type I IFN-induced, NKT cell-mediated negative control of CD8 T cell priming by dendritic cells.. J Immunol 181(3):1633-43 PMID: 18641299
- 6. Kanagawa O et al.. 2000. Thymic and postthymic regulation of diabetogenic CD8 T cell development in TCR transgenic nonobese diabetic (NOD) mice.. J Immunol 164(10):5466-73 PMID: 10799914
- 7. Chen W et al.. 2004. The role and mechanisms of double negative regulatory T cells in the suppression of immune responses.. Cell Mol Immunol 1(5):328-35 PMID: 16285891
- 8. Tanigaki K et al.. 2004. Regulation of alphabeta/gammadelta T cell lineage commitment and peripheral T cell responses by Notch/RBP-J signaling.. Immunity 20(5):611-22 PMID: 15142529
